A BILL 
To educate health care providers and the public on biosimilar 
biological products, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Advancing Education 
4
on Biosimilars Act of 2021’’. 
5
SEC. 2. EDUCATION ON BIOLOGICAL PRODUCTS. 
6
Subpart 1 of part F of title III of the Public Health 
7
Service Act (42 U.S.C. 262 et seq.) is amended by adding 
8
at the end the following: 
9
21:12 May 11, 2021
H1873
2 
•HR 1873 IH
‘‘SEC. 352A. EDUCATION ON BIOLOGICAL PRODUCTS. 
1
‘‘(a) INTERNET WEBSITE.— 
2
‘‘(1) IN GENERAL.—The Secretary may main-
3
tain and operate an internet website to provide edu-
4
cational materials for health care providers, patients, 
5
and caregivers, regarding the meaning of the terms, 
6
and the standards for review and licensing of, bio-
7
logical products, including biosimilar biological prod-
8
ucts and interchangeable biosimilar biological prod-
9
ucts. 
10
‘‘(2) CONTENT.—Educational materials pro-
11
vided under paragraph (1) may include— 
12
‘‘(A) explanations of key statutory and 
13
regulatory terms, including ‘biosimilar’ and 
14
‘interchangeable’, and clarification regarding 
15
the use of interchangeable biosimilar biological 
16
products; 
17
‘‘(B) information related to development 
18
programs for biological products, including bio-
19
similar biological products and interchangeable 
20
biosimilar biological products and relevant clin-
21
ical considerations for prescribers, which may 
22
include, as appropriate and applicable, informa-
23
tion related to the comparability of such biologi-
24
cal products; 
25
21:12 May 11, 2021
H1873
3 
•HR 1873 IH
‘‘(C) an explanation of the process for re-
1
porting adverse events for biological products, 
2
including biosimilar biological products and 
3
interchangeable biosimilar biological products; 
4
and 
5
‘‘(D) an explanation of the relationship be-
6
tween biosimilar biological products and inter-
7
changeable biosimilar biological products li-
8
censed under section 351(k) and reference 
9
products (as defined in section 351(i)), includ-
10
ing the standards for review and licensing of 
11
each such type of biological product. 
12
‘‘(3) FORMAT.—The educational materials pro-
13
vided under paragraph (1) may be— 
14
‘‘(A) in formats such as webinars, con-
15
tinuing education modules, videos, fact sheets, 
16
infographics, stakeholder toolkits, or other for-
17
mats as appropriate and applicable; and 
18
‘‘(B) tailored for the unique needs of 
19
health care providers, patients, caregivers, and 
20
other audiences, as the Secretary determines 
21
appropriate. 
22
‘‘(4) OTHER INFORMATION.—In addition to the 
23
information described in paragraph (2), the Sec-
24
retary shall continue to publish— 
25
21:12 May 11, 2021
H1873
4 
•HR 1873 IH
‘‘(A) the action package of each biological 
1
product licensed under subsection (a) or (k) of 
2
section 351; or 
3
‘‘(B) the summary review of each biological 
4
product licensed under subsection (a) or (k) of 
5
section 351. 
6
‘‘(5) CONFIDENTIAL AND TRADE SECRET IN-
7
FORMATION.—This subsection does not authorize 
8
the disclosure of any trade secret, confidential com-
9
mercial or financial information, or other matter de-
10
scribed in section 552(b) of title 5. 
11
‘‘(b) CONTINUING EDUCATION.—The Secretary shall 
12
advance education and awareness among health care pro-
13
viders regarding biological products, including biosimilar 
14
biological products and interchangeable biosimilar biologi-
15
cal products, as appropriate, including by developing or 
16
improving continuing education programs that advance 
17
the education of such providers on the prescribing of, and 
18
relevant clinical considerations with respect to, biological 
19
products, including biosimilar biological products and 
20
interchangeable biosimilar biological products.’’. 
21
Æ 
21:12 May 11, 2021
H1873
